Skip to main content
SpringerLink
Log in
Book cover

Hepatocellular Carcinoma pp 163–166Cite as

HCC and Its Microenvironment

  • Chapter
  • First Online:

  • 1986 Accesses

Part of the book series: Current Clinical Oncology ((CCO))

Abstract

HCC typically arises on the basis of a chronically inflammed background liver. This background or microenvironment has been shown to be part of a two-way influence, in which the growing tumor can damage the liver parenchyma, and the microenvironment can influence the tumor biology. The latter occurs as a result of multiple factors, including immune cells and their cytokines, platelets and their growth and inflammatory factors and endothelial cells. The resulting tumor-associated microenvironment has been found to contain prognostic molecular signatures, to influence responses to chemotherapy, to be important in the development of the growing tumor vasculature, the immune response and to contribute in many important ways to HCC aggressiveness.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY, Villanueva A, Newell P, Ikeda K, Hashimoto M, Watanabe G, Gabriel S, Friedman SL, Kumada H, Llovet JM, Golub TR. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 2009;69(18):7385–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan JA, Glickman JN, Ikeda K, Hashimoto M, Watanabe G, Daidone MG, Roayaie S, Schwartz M, Thung S, Salvesen HB, Gabriel S, Mazzaferro V, Bruix J, Friedman SL, Kumada H, Llovet JM, Golub TR. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 2008;359(19):1995–2004.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, Kammula US, Chen Y, Qin LX, Tang ZY, Wang XW. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 2006;10(2):99–111.

    Article  CAS  PubMed  Google Scholar 

  4. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, Simon R, Li Y, Robles AI, Chen Y, Ma ZC, Wu ZQ, Ye SL, Liu YK, Tang ZY, Wang XW. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med. 2003;9(4):416–23.

    Article  CAS  PubMed  Google Scholar 

  5. Woo HG, Park ES, Cheon JH, Kim JH, Lee JS, Park BJ, Kim W, Park SC, Chung YJ, Kim BG, Yoon JH, Lee HS, Kim CY, Yi NJ, Suh KS, Lee KU, Chu IS, Roskams T, Thorgeirsson SS, Kim YJ. Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin Cancer Res. 2008;14(7):2056–64.

    Article  CAS  PubMed  Google Scholar 

  6. Okamoto M, Utsunomiya T, Wakiyama S, et al. Specific gene-expression profiles of noncancerous liver tissue predict the risk for multicentric occurrence of hepatocellular carcinoma in hepatitis C virus-positive patients. Ann Surg Oncol. 2006;13:947–54.

    Article  PubMed  Google Scholar 

  7. Jiang J, Gusev Y, Aderca I, et al. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res. 2008;14:419–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21:309–22.

    Article  CAS  PubMed  Google Scholar 

  9. Yamashita T, Forgues M, Wang W, et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 2008;68:1451–61.

    Article  CAS  PubMed  Google Scholar 

  10. Mínguez B, Hoshida Y, Villanueva A, Toffanin S, et al. Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol. 2011;55:1325–31.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Nault JC, De Reyniès A, Villanueva A, Calderaro J, et al. A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology. 2013;145:176–87.

    Article  CAS  PubMed  Google Scholar 

  12. Giannelli G, Rani B, Dituri F, Cao Y, Palasciano G. Moving towards personalised therapy in patients with hepatocellular carcinoma: the role of the microenvironment. Gut. 2014;63:1668–76.

    Article  CAS  PubMed  Google Scholar 

  13. Hernandez-Gea Virginia, Toffanin Sara, Friedman Scott L, Josep M. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology. 2013;144:512–27.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Yang JD, Nakamura I, Roberts LR. The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol. 2011;21:35–43.

    Article  CAS  PubMed  Google Scholar 

  15. Capece D, Fischietti M, Verzella D, Gaggiano A, et al. The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. Biomed Res Int. 2013;2013:187204.

    Article  PubMed  Google Scholar 

  16. Tu T, Budzinska MA, Maczurek AE, Cheng R, et al. Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development. Int J Mol Sci. 2014;15:9422–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Carr BI, Guerra V, Giannini EG, et al. Association of abnormal plasma bilirubin with aggressive hepatocellular carcinoma phenotype. Semin Oncol. 2014;41(2):252–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Yan C, Huo X, Wang S, Feng Y, Gong Z. Stimulation of hepatocarcinogenesis by neutrophils upon induction of oncogenic kras expression in transgenic zebrafish. J Hepatol. 2015;63:420–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Yang Z, Zhang J, Lu Y, Xu Q et al. Aspartate aminotransferase-lymphocyte ratio index and systemic immune-inflammation index predict overall survival in HBV-related hepatocellular carcinoma patients after transcatheter arterial chemoembolization. Oncotarget. 2015. doi:10.18632/oncotarget.5719. [Epub ahead of print].

  20. Petrick JL, Sahasrabuddhe VV, Chan AT, Alavanja MC et al. NSAID use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: the liver cancer pooling project. Cancer Prev Res (Phila). 2015. [Epub ahead of print].

    Google Scholar 

  21. Zhou DS, Xu L, Luo YL, He FY, et al. Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization. World J Gastroenterol. 2015;21:5582–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Lu SN, Wang JH, Liu SL, Hung CH, et al. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. Cancer. 2006;107:2212–22.

    Article  PubMed  Google Scholar 

  23. Carr BI, Guerra V. Hepatocellular carcinoma size: platelets, γ-glutamyl transpeptidase, and alkaline phosphatase. Oncology. 2013;85:153–9.

    Article  CAS  PubMed  Google Scholar 

  24. Carr BI, Guerra V, De Giorgio M, Fagiuoli S, Pancoska P. Small hepatocellular carcinomas and thrombocytopenia. Oncology. 2012;83:331–8.

    Article  CAS  PubMed  Google Scholar 

  25. Goubran HA, Burnouf T, Radosevic M, El-Ekiaby M. The platelet-cancer loop. Eur J Intern Med. 2013;24:393–400.

    Article  CAS  PubMed  Google Scholar 

  26. Yan M, Jurasz P. The role of platelets in the tumor microenvironment: From solid tumors to leukemia. Biochim Biophys Acta. 2015. [Epub].

    Google Scholar 

  27. Carr BI, Guerra V. Thrombocytosis and hepatocellular carcinoma. Dig Dis Sci. 2013;58:1790–6.

    Google Scholar 

  28. Carr BI, Lin CY, Lu SN. Platelet-related phenotypic patterns in hepatocellular carcinoma patients. Semin Oncol. 2014;41(3):415–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Carr BI, Cavallini A, D’Alessandro R, Refolo MG, et al. Platelet extracts induce growth, migration and invasion in human hepatocellular carcinoma in vitro. BMC Cancer. 2014;14:43.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Sitia G, Aiolfi R, Di Lucia P, Mainetti M, et al. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci USA. 2012;109:E2165–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Sitia G, Iannacone M, Guidotti LG. Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma. J Hepatol. 2013;59:1135–8.

    Article  CAS  PubMed  Google Scholar 

  32. D’Alessandro R, Refolo MG, Lippolis C, et al. Antagonism of Sorafenib and Regorafenib actions by platelet factors in hepatocellular carcinoma cell lines. BMC Cancer. 2014;14:351.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Refolo MG, D’Alessandro R, Lippolis C, et al. Modulation of Doxorubicin mediated growth inhibition of hepatocellular carcinoma cells by platelet lysates. Anticancer Agents Med Chem. 2014;14(8):1154–60.

    Article  CAS  PubMed  Google Scholar 

  34. Dhillon AS, Hagan S, Rath O, et al. MAP kinase signaling pathways in cancer. Oncogene. 2007;26:3279–90.

    Article  CAS  PubMed  Google Scholar 

  35. Demers M, Wagner DD. Targeting platelet function to improve drug delivery. Oncoimmunology. 2012;1(1):100–2.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Koti M, Siu A, Clément I, et al. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer. Br J Cancer. 2015;112:1215–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Sun Y1, Nelson PS. Molecular pathways: involving microenvironment damage responses in cancer therapy resistance. Clin Cancer Res 2012;18:4019–25.

    Google Scholar 

  38. Chen H, Lan X, Liu M, et al. Direct TGF-β1 signaling between activated platelets and pancreatic cancer cells primes cisplatin insensitivity. Cell Biol Int. 2013;37(478):484.

    Google Scholar 

  39. Alexia C, Fallot G, Lasfer M, et al. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. Biochem Pharmacol. 2004;68(6):1003–15.

    Article  CAS  PubMed  Google Scholar 

  40. D’Alessandro R, Refolo MG, Lippolis C, et al. Modulation of regorafenib effects on HCC cell lines by epidermal growth factor. Cancer Chemother Pharmacol. 2015;75(6):1237–45.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Lippolis C, Refolo MG, D’Alessandro R, Carella N et al. Resistance to multikinase inhibitor actions mediated by insulin like growth factor-1. J Exp Clin Cancer Res. 2015;34:90.

    Google Scholar 

  42. D’Alessandro R, Messa C, Refolo MG, Carr BI. Modulation of sensitivity and resistance to multikinase inhibitors by microenvironmental platelet factors in HCC. Expert Opin Pharmacother. 2015;19:1–8.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Izmir Biomedicine and Genome Center, Dokuz Eylül University, Izmir, Turkey

    Brian I. Carr

  2. Lusaka Apex Medical University, Lusaka, Zambia

    Brian I. Carr

Authors
  1. Brian I. Carr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Brian I. Carr .

Editor information

Editors and Affiliations

  1. Dokuz Eylul University, Izmir Biomedicine and Genome Center Dokuz Eylul University, Izmir, Izmir, Turkey

    Brian I. Carr

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Carr, B.I. (2016). HCC and Its Microenvironment. In: Carr, B. (eds) Hepatocellular Carcinoma. Current Clinical Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-34214-6_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-34214-6_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-34212-2

  • Online ISBN: 978-3-319-34214-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation